Welcome to our dedicated page for Waters SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Waters Corporation (NYSE: WAT) filings with the U.S. Securities and Exchange Commission (SEC), along with AI-generated summaries to help interpret key disclosures. Waters files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that cover its operations in analytical instruments, separations technologies, and software serving the life, materials, food, and environmental sciences.
For Waters, 10-K and 10-Q filings are central resources for understanding its business segments, end markets, and risk factors. These documents discuss topics such as the company’s role in pharmaceutical, industrial, and academic/government applications, as well as its global footprint in over 100 countries. AI summaries can highlight sections related to recurring revenue, instrument trends, and investments in areas like bioanalytical characterization and bioseparations.
Form 8-K filings are particularly important for tracking material events. Recent 8-Ks describe quarterly financial results, provide press releases as exhibits, and outline the definitive agreements for a Reverse Morris Trust transaction that will combine BD’s Biosciences and Diagnostic Solutions business with Waters. Other 8-Ks discuss the effectiveness of registration statements on Form S-4 and Form 10 related to that transaction and the mailing of a proxy statement/prospectus to Waters shareholders.
Investors can also use this page to locate information on governance matters and potential insider activity through ownership reports referenced in Waters’ filings. Real-time updates from EDGAR, combined with AI-powered explanations, are intended to make complex regulatory documents more accessible by summarizing key terms, conditions, and implications for WAT shareholders and stakeholders following Waters’ evolution in life science and diagnostics markets.
Waters Corp (WAT) director equity grant reported
Director Mark Vergnano reported receiving 307 shares of Waters Corp common stock on January 2, 2026, at a stated price of $0. These shares are restricted and the filing states that restrictions lapse on January 2, 2027. Following this grant, he beneficially owns 4,517 common shares directly.
On the same date, he was also granted a stock option covering 828 shares of common stock with an exercise price of $381.96 per share. The option becomes fully exercisable on January 2, 2027 and expires on January 2, 2036. After this grant, he holds 828 derivative securities (stock options) directly.
Waters Corp director reports new stock awards. Director Christopher A. Kuebler reported receiving 307 shares of Waters Corp common stock on January 2, 2026 as a restricted stock grant at a price of $0 per share. These shares are subject to restrictions that lapse in full on January 2, 2027. Following this grant, he beneficially owns 17,785 common shares directly.
On the same date, he was granted a stock option covering 828 shares of common stock with an exercise price of $381.96 per share. All 828 option shares will vest and become exercisable on January 2, 2027, and the option expires on January 2, 2036. Both the stock and option holdings are reported as directly owned.
Waters Corp director reports new stock and option awards. A director of Waters Corp (WAT) acquired 307 shares of common stock on 01/02/2026 at a price of $0, increasing direct beneficial ownership to 3,253.3 shares. These 307 shares are restricted and will fully vest on January 2, 2027.
The director also received a stock option for 828 shares of common stock with an exercise price of $381.96 per share, granted on 01/02/2026. All 828 option shares will vest and become exercisable on January 2, 2027 and will expire on January 2, 2036, if not exercised.
Waters Corp director equity grant: A director of Waters Corp received new equity awards on January 2, 2026. The director was granted 307 shares of common stock at a price of $0, which are restricted and scheduled to fully lapse on January 2, 2027. After this grant, the director beneficially owns 2,279 shares of Waters common stock directly.
The director was also granted a stock option covering 828 shares of Waters common stock at an exercise price of $381.96 per share. All 828 option shares are scheduled to vest and become exercisable on January 2, 2027, and the option expires on January 2, 2036. These awards are typical director compensation in equity form, aligning the director’s holdings with the company’s stock performance.
Waters Corp director reports equity awards in a Form 4 dated 01/02/2026. The reporting person, a director of Waters Corp, acquired 307 shares of common stock at a price of $0, bringing total directly held common shares to 1,332.
The filing also shows a grant of a stock option covering 828 shares of common stock with an exercise price of $381.96 per share, expiring on 01/02/2036. All 307 common shares are restricted stock that will fully lapse in restrictions on January 2, 2027, and all 828 option shares will vest and become exercisable on January 2, 2027.
Waters Corp director reports new stock and option awards. Director Linda Baddour reported receiving 307 shares of Waters common stock on January 2, 2026, at a stated price of $0, increasing her directly held stake to 2,876 shares. These shares are restricted and all restrictions lapse on January 2, 2027, meaning they fully vest on that date.
On the same date, she also received a stock option for 828 shares of common stock with an exercise price of $381.96 per share. The option becomes fully exercisable on January 2, 2027 and expires on January 2, 2036. Following this grant, she directly holds options covering 828 shares in addition to her common stock holdings.
Waters Corp director Flemming Ornskov reported new equity awards, including 307 shares of common stock and a stock option for 828 shares, both dated January 2, 2026. The 307 shares are restricted stock that remain subject to restrictions until January 2, 2027, when all of them are scheduled to vest. The option has an exercise price of $381.96 per share and will become fully exercisable on January 2, 2027, with an expiration date of January 2, 2036. After these transactions, the director beneficially owns 4,935 shares of Waters common stock directly and holds 828 stock options.
Waters Corp director Wei Jiang reported new equity awards in the company. On December 31, 2025, Jiang received 59.79 common stock units in lieu of cash director fees under Waters’ 1996 Non-Employee Director Deferred Compensation Plan. These units convert into the same number of common shares on January 1, 2035 based on a prior election.
On January 2, 2026, Jiang acquired 307 shares of common stock at $0, which are subject to restrictions that lapse in full on January 2, 2027, increasing beneficial ownership to 2,918.27 shares held directly. The same day, Jiang was also granted a stock option to buy 828 shares at an exercise price of $381.96 per share, which will vest and become exercisable on January 2, 2027 and expire on January 2, 2036.
Waters CorpDecember 31, 2025, she received 59.79 common stock units in lieu of cash director fees under the 1996 Non-Employee Director Deferred Compensation Plan. These units convert to common shares on a one-for-one basis, with distribution scheduled for January 1, 2027, based on a prior election.
On January 2, 2026, she was granted 307 shares of restricted common stock, which remain subject to restrictions that lapse in full on January 2, 2027. She also received a stock option for 828 shares at an exercise price of $381.96 per share. All 828 option shares will vest and become exercisable on January 2, 2027. After these transactions, she directly owned 1,126.07 shares of common stock and 828 stock options.
Waters Corporation and Becton, Dickinson and Company are moving forward with a complex Reverse Morris Trust transaction to combine BD’s Biosciences & Diagnostic Solutions business with Waters. BD has formed Augusta SpinCo Corporation, transferred the BDS assets and liabilities into SpinCo, and obtained effectiveness of SpinCo’s Form 10 and Waters’ Form S-4. BD will distribute all SpinCo shares to its shareholders, and SpinCo will then merge into a Waters subsidiary so SpinCo becomes a wholly owned Waters unit.
Waters is seeking shareholder approval at a January 27, 2026 virtual special meeting to issue shares of Waters common stock in the merger, with up to 60,737,462 shares registered for issuance. The structure is designed so BD shareholders ultimately receive Waters shares in a generally tax-efficient manner, with BD shareholders expected to own more than 50% of Waters after the merger to preserve favorable U.S. federal income tax treatment.